Wedbush Upgrades Anthera Pharma (ANTH) to Outperform; PEARL-SC Interim Analysis Shows B-Cell Reduction
Tweet
Share
E-mailGet Alerts ANTH Hot Sheet
Price: $0.00 --0%
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush upgraded Anthera Pharma (NASDAQ: ANTH) from Neutral to Outperform, price target raised $1 to $8.
Wedbush analyst says, "Anthera announced yesterday that interim data
showed a statistically significant B-cell reduction among systemic lupus
erythematosus (SLE) patients administered A-623 in the ongoing PEARL-SC study. Recall that PEARL-SC is a randomized double-blind Phase 2b study evaluating monthly and weekly subcutaneous A-623 for SLE with a primary endpoint of clinical improvement according to the SLE responder index at 24 weeks. Also recall that A-623 is an inhibitor of B-cell activating factor (BAFF), and B-cell proliferation is associated with SLE. While there is strong evidence to suggest that lowering B-cell activity is key to treating SLE (demonstrated by HGSI’s Benlysta), the lupus drug development space is littered with failed treatments that have reduced B-cells but did not demonstrate significant improvements in SLE disease activity (examples are Rituxan and Atacicept)."
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $5.79 yesterday.
Wedbush analyst says, "Anthera announced yesterday that interim data
showed a statistically significant B-cell reduction among systemic lupus
erythematosus (SLE) patients administered A-623 in the ongoing PEARL-SC study. Recall that PEARL-SC is a randomized double-blind Phase 2b study evaluating monthly and weekly subcutaneous A-623 for SLE with a primary endpoint of clinical improvement according to the SLE responder index at 24 weeks. Also recall that A-623 is an inhibitor of B-cell activating factor (BAFF), and B-cell proliferation is associated with SLE. While there is strong evidence to suggest that lowering B-cell activity is key to treating SLE (demonstrated by HGSI’s Benlysta), the lupus drug development space is littered with failed treatments that have reduced B-cells but did not demonstrate significant improvements in SLE disease activity (examples are Rituxan and Atacicept)."
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $5.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic CFO Krishna Rao is leading early IPO meetings with investors and has not discussed valuation - CNBC
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
